RocketVax has successfully completed another round of financing; The development of the second-generation COVID-19 vaccine moves forward
Dr. Vladimir Cmiljanovic is a recipient of the 2023 Nikola Tesla Spirit Award
Swiss Rockets further strengthens the development of its phase II cancer drug candidate bimiralisib
RocketVax AG Announces New Milestones in the Development of Second-Generation COVID-19 Vaccines
Burkhard Frey joins Swiss Rockets AG as Chief Commercial Officer
Dr. Milan Crnogorac joins Swiss Rockets AG as Chief Technology Officer
Cleveland Clinic Appoints Prof. Alex A. Adjei, M.D., Ph.D., as Chair of Taussig Cancer Institute
RocketVax SARS-CoV-2 Vaccine (RVX-sCPD9) Significantly Outperforms mRNA and Adenovirus Vector-Based Technologies in Animal Models
RocketVax strengthens its technology portfolio and Covid-19 vaccine development through broad-based partnerships
Swiss Rockets AG appoints a Chief Financial Officer
Dr. Vladimir Cmiljanovic is the recipient of the 2021 Nikola Tesla Award for the achievements in the field of science
Alex A. Adjei is the recipient of the 2021 ESMO Lifetime Achievement Award
RocketVax successfully raises CHF 7.2 million of seed funding
Batavia Biosciences to develop innovative clinical process for RocketVax’s second generation COVID-19 vaccine
Basel government approves one million for research to develop novel vaccine against SARS-CoV-2 coronavirus
